| Literature DB >> 22935748 |
Tomohiro Yamada1, Tomohide Yoshimura, Naoya Kitamura, Eri Sasabe, Seiji Ohno, Tetsuya Yamamoto.
Abstract
Low-grade myofibroblastic sarcoma (LGMS) is a rare, malignant tumor with myofibroblastic differentiation. Despite it being classified as a distinct entity by the World Health Organization, a few cases were reported in the oral and maxillofacial region. Here, a LGMS developed on the palate of a 73-year-old man who presented with a 1-cm tumor on the posterior border of the palate. Based on the histological and immunohistochemical features, a diagnosis of LGMS was established. The tumor was resected, and no recurrence was observed over 2 years. Although the tongue is the most preferred site for LGMS, it may occur in any region of the oral cavity.Entities:
Mesh:
Year: 2012 PMID: 22935748 PMCID: PMC3465011 DOI: 10.1038/ijos.2012.49
Source DB: PubMed Journal: Int J Oral Sci ISSN: 1674-2818 Impact factor: 6.344
Figure 1Intraoral photo at the initial visit. An elastic, hard, 10 mm×10 mm mass is seen on the posterior border of the palate.
Figure 2Histology of the tumor. The tumor cells had round-shaped or spindle nuclei, and the cytoplasm was eosinophilic. Mitotic cells were sparse, and atypical cells with large nuclei were observed. Hematoxylin and eosin staining, a: ×40; b: ×200.
Figure 3Immunohistochemical staining of the tumor. The spindle cells were focally immunoreactive for α-SMA (a: ×200) and MIB-1 (b: ×200). α-SMA, α-smooth muscle actin.
Immunohistochemical findings
| Markers | Immunoreactivity |
|---|---|
| α-SMA | + |
| Muscle-specific actin | + |
| EMA | − |
| S-100 | − |
| AE1/AE3 | − |
| CD34 | − |
| MIB-1 LI | 10% |
EMA, epithelial membrane antigen; α-SMA, α-smooth muscle actin.
Immunohistochemistry revealed that most spindle cells were immunoreactive for muscle specific actin, and focally for α-SMA and MIB-1, whereas immunostaining for other markers such as EMA, S-100 protein, cytokeratin (AE1/AE3) and CD34 was not observed.
Figure 4Intraoral photo 2 years after removal of the tumor. There is only scar on the posterior border of the palate, and no reoccurrence was observed.
LGMS in the oral and maxillofacial region
| Case | Reference | Gender | Age/year | Site | Size/cm | Treatment | Reoccurrence |
|---|---|---|---|---|---|---|---|
| 1 | 16 | M | 75 | Parietal | NA | NA | Y |
| 2 | 16 | M | 85 | Face | NA | NA | N |
| 3 | 17 | F | 43 | Face | 1.5 | NA | N |
| 4 | 18 | F | 12 | Maxilla | 6.0 | NA | Y |
| 5 | 18 | M | 18 | Maxilla | NA | NA | Y |
| 6 | 18 | F | 9 | Mandible | NA | NA | Y |
| 7 | 18 | F | 13 | Tonsil | NA | NA | N |
| 8 | 18 | F | 9 | Mandible | NA | NA | N |
| 9 | 9 | F | 51 | Tongue | 2.5 | Local excision | N |
| 10 | 9 | M | 70 | Tongue | 1.4 | Local excision | N |
| 11 | 9 | M | 24 | Tongue | 1.5 | Local excision | N |
| 12 | 9 | M | 66 | Tongue | 1.8 | Wide excision | N |
| 13 | 9 | M | 19 | Mandible | 3.5 | Local excision, RT, CT | N |
| 14 | 19 | F | 71 | Parotid gland | 1.7 | Wide excision | N |
| 15 | 5 | M | 24 | Maxillary sinus | 4.0 | Wide excision | N |
| 16 | 5 | M | 49 | Maxilla | 8.0 | Wide excision | Y |
| 17 | 3 | M | 41 | Hard palate | 3.5 | Wide excision | N |
| 18 | 3 | M | 35 | Palate | 1.6 | Local excision | Y |
| 19 | 3 | F | 54 | Gingiva | 1.5 | Local excision | Y |
| 20 | 20 | F | 77 | Nasal cavity | 3.0 | Local excision | Y |
| 21 | 14 | F | 8 | Pterygoid region | 6.0 | Wide excision, CT | N |
| 22 | 14 | F | 2 | Temporal fossa | 2.9 | Wide excision | N |
| 23 | 21 | F | 37 | Cheek | 2.0 | Wide excision | N |
| 24 | 22 | F | 24 | Tongue | 2.0 | Local excision | N |
| 25 | 23 | M | 42 | Parapharyngeal space | NA | RT, CT | Y (dead) |
| 26 | 12 | M | 41 | Tongue | 1.7 | Local excision | Y |
| 27 | 24 | M | 28 | Lower lip | 2.0 | local excision | NA |
| 28 | 7 | M | 74 | Nasal cavity | 3.0 | NA | Y |
| 29 | 7 | M | 14 | Ethmoid sinus | 4.5 | NA | Y |
| 30 | 7 | M | 14 | Nasal cavity | 5.0 | NA | Y |
| 31 | 10 | M | 51 | Mandible | 3.0 | Wide excision | N |
| 32 | 10 | F | 61 | Tongue | 4.0 | Wide excision | N |
| 33 | 4 | F | 56 | Tongue base | 2.0 | Local excision, RT | N |
| 34 | 15 | M | 54 | Mandible | 6.0 | Local excision | N |
| 35 | current case | M | 73 | Palate | 1.0 | Local excision | N |
CT, chemotherapy; RT, radiotherapy.
Reoccurrence and tumor site
| Site | Reoccurrence cases/total cases | reoccurrence rate/% |
|---|---|---|
| Tongue | 1/8 | 12.5 |
| Jaw (incl. gingiva) | 5/9 | 55.5 |
| Nasal cavity/paranasal sinus | 4/5 | 80.0 |
| Palate | 1/3 | 33.3 |
| Deep tissue space | 2/4 | 50.0 |
| Others | 0/5 | 0.0 |
| Total | 13/34 | 38.2 |
Reoccurrence rate is the highest when tumor is sited in nasal cavity/paranasal sinus. Second is jawbone, followed by deep tissue space.